Read by QxMD icon Read

ovarian cancer cytoreduction

Hee Seung Kim, Robert E Bristow, Suk-Joon Chang
OBJECTIVE: The majority of advanced ovarian cancer patients have peritoneal carcinomatosis involving from the pelvis to upper abdomen, which is a major obstacle to optimal cytoreduction. Since total parietal peritonectomy was introduced for treating peritoneal carcinomatosis from colorectal cancer [3], similar surgical techniques including pelvic peritonectomy have been applied in advanced ovarian cancer with peritoneal carcinomatosis [1], and these can increase the rate of complete cytoreduction up to 60% [2]...
October 13, 2016: Gynecologic Oncology
Atul B Shinagare, Chong Hyun Suh, Kyung Won Kim, Bhanusupriya Somarouthu, Annick D Van den Abbeele, Nikhil H Ramaiya
PURPOSE: To create and validate an evidence-based prediction rule to optimize use of follow-up chest CT for ovarian cancer. METHODS: In this Institutional Review Board-approved retrospective study performed at two academic medical centers, electronic medical records from January through December 2013 at center 1 (USA) and January 2012 through December 2013 at center 2 (South Korea) were searched to identify consecutive chest CTs performed within 5 years of initial cytoreductive surgery in patients with pathologically proven ovarian cancer...
October 6, 2016: Journal of the American College of Radiology: JACR
Wankyu Eo, Hong-Bae Kim, Yong Joo Lee, Dong Soo Suh, Ki Hyung Kim, Heungyeol Kim
OBJECTIVE: To determine whether the preoperative lymphocyte-monocyte ratio (LMR) is a predictor of suboptimal cytoreduction in advanced-stage epithelial ovarian cancer (EOC). METHODS: Preoperative clinico-pathologic and hematologic parameters were reviewed in a total of 154 patients with EOC submitted to primary cytoreductive surgery. Patients were categorized into two different groups according to the results of cytoreductive surgery: optimal and suboptimal cytoreduction...
2016: Journal of Cancer
Ahmed Al-Niaimi, Elizabeth L Dickson, Cassandra Albertin, Jennifer Karnowski, Cassandra Niemi, Ryan Spencer, Mian M K Shahzad, Shitanshu Uppal, Sandeep Saha, Laurel Rice, Amy Mc Nally
OBJECTIVE: To quantify the impact of perioperative β blocker use on survival after primary cytoreductive surgery for epithelial ovarian cancer. METHODS: We conducted a multi-center retrospective study of all women who underwent primary cytoreductive surgery for ovarian cancer (2000-2010). One institution had routinely used perioperative β blockers for patients "at risk" for coronary events. The other institution did not routinely use perioperative β blockers...
September 29, 2016: Gynecologic Oncology
Peter G Rose, James J Java, Mark A Morgan, Angeles Alvarez-Secord, Joshua P Kesterson, Frederick B Stehman, David P Warshal, William T Creasman, Parviz Hanjani, Robert T Morris, Larry J Copeland
PURPOSE: GOG 152 was a randomized trial of secondary cytoreductive surgery (SCS) in patients with suboptimal residual disease (residual tumor nodule >1cm in greatest diameter) following primary cytoreductive surgery for advanced stage ovarian cancer. The current analysis was undertaken to evaluate the impact of disease findings at SCS on progression-free survival (PFS) and overall survival (OS). METHODS: Among the 550 patients enrolled on GOG-152, two-hundred-sixteen patients were randomly assigned following 3cycles of cisplatin and paclitaxel to receive SCS...
September 27, 2016: Gynecologic Oncology
E S Paik, E J Heo, H J Choi, A Yoon, Y-Y Lee, C Choi, T-J Kim, J-W Lee, B-G Kim, D-S Bae, D S Choi
No abstract text is available yet for this article.
November 2015: Journal of Minimally Invasive Gynecology
Aurélie Pelissier, Aurélie Roulot, Béatrice Guéry, Claire Bonneau, Dominique Bellet, Roman Rouzier
BACKGROUND: The aim of this study is to evaluate a new tumour marker, HE4, and to compare it with CA125 in predicting optimal cytoreduction and response to chemotherapy. Thirty patients with advanced epithelial ovarian cancer and multiple sera harvested during neoadjuvant chemotherapy (NAC) were included. RESULTS: Based on ROC curves analysis, CA125 ≤ 75 UI/ml and HE4 ≤ 252 pmol/L after the 3rd cycles of NAC, with a sensitivity of 93.7 % and a specificity of 92...
September 27, 2016: Journal of Ovarian Research
Jerec W Ricci, Debbie M Lovato, Virginia Severns, Larry A Sklar, Richard S Larson
Chemotherapeutic resistance remains a challenge in the treatment of ovarian carcinoma, especially in recurrent disease. Despite the fact that most patients with newly diagnosed tumors attain complete remission following cytoreductive surgery and chemotherapy, ovarian carcinoma has a recurrence rate that exceeds 75%. The ATP Binding Cassette family G member 2 (ABCG2) efflux protein has been described as one mechanism that confers multiple drug resistance (MDR) to solid tumors and contributes to topotecan (TPT) resistance in ovarian carcinoma...
September 26, 2016: Molecular Cancer Therapeutics
Nienke Zwakman, Rafli van de Laar, Toon Van Gorp, Petra L M Zusterzeel, Marc P M L Snijders, Isabel Ferreira, Leon F A G Massuger, Roy F P M Kruitwagen
OBJECTIVE: In patients with advanced stage epithelial ovarian cancer (EOC) the volume of residual tumor after debulking is known as prognostic factor for survival. We wanted to examine the relationship between postoperative decline in serum CA125 and residual disease after cytoreductive surgery and evaluate perioperative changes in serum CA125 levels as predictor for disease-specific survival. METHODS: A retrospective study was conducted of patients with FIGO stage IIb-IV EOC treated with cytoreductive surgery, followed by chemotherapy between 1996 and 2010 in three hospitals in the Southeastern region of the Netherlands...
September 12, 2016: Journal of Gynecologic Oncology
Sham S Kakar, Christopher A Worth, Zhenglong Wang, Kelsey Carter, Mariusz Ratajczak, Pranesh Gunjal
Ovarian cancer is a highly aggressive and deadly disease. Currently, the treatment for ovarian cancer entails cytoreductive surgery followed by chemotherapy, mainly cisplatin or carboplatin combined with paclitaxel. Although this regimen is initially effective in a high percentage of cases, unfortunately, after few months of initial treatment, tumor relapse occurs due to platinum-resistance. DOXIL (liposomal preparation of doxorubicin) is a choice of drug for recurrent ovarian cancer. However, its response rate is very low and is accompanied by myocardial toxicity...
2016: Journal of Cancer Stem Cell Research
V Lopez-Lopez, P A Cascales-Campos, J Gil, L Frutos, R J Andrade, M Fuster-Quiñonero, E Feliciangeli, E Gil, P Parrilla
PURPOSE: To evaluate the clinical usefulness of the results obtained with (18)F-FDG PET/CT in relation to CT in the preoperative staging of patients with peritoneal carcinomatosis secondary to primary or recurrent ovarian cancer candidates to cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC). MATERIAL AND METHODS: A retrospective study comparing the results obtained with CT and (18)F-FDG PET/CT in the preoperative evaluation of a series of 59 patients was performed...
October 2016: European Journal of Radiology
Thomas Vinotha, Thomas Anitha, Sebastian Ajit, Chandy Rachel, Peedicayil Abraham
INTRODUCTION: Patients referred with inadequately staged ovarian malignancies present a clinical dilemma. We report our experience with completion surgery in ovarian cancer. AIMS AND OBJECTIVES: To determine the benefits and risks of completion surgery in women with ovarian cancer who presented after having had inadequate primary surgery. METHODS: A retrospective case series of 30 women with ovarian cancer and one with fallopian tube cancer who had inadequate primary surgery underwent completion surgery at gynaecologic oncology unit in a tertiary level hospital in Tamil Nadu, India...
October 2016: Journal of Obstetrics and Gynaecology of India
Alexi A Wright, Kari Bohlke, Deborah K Armstrong, Michael A Bookman, William A Cliby, Robert L Coleman, Don S Dizon, Joseph J Kash, Larissa A Meyer, Kathleen N Moore, Alexander B Olawaiye, Jessica Oldham, Ritu Salani, Dee Sparacio, William P Tew, Ignace Vergote, Mitchell I Edelson
PURPOSE: To provide guidance to clinicians regarding the use of neoadjuvant chemotherapy and interval cytoreduction among women with stage IIIC or IV epithelial ovarian cancer. METHODS: The Society of Gynecologic Oncology and the American Society of Clinical Oncology convened an Expert Panel and conducted a systematic review of the literature. RESULTS: Four phase III clinical trials form the primary evidence base for the recommendations. The published studies suggest that for selected women with stage IIIC or IV epithelial ovarian cancer, neoadjuvant chemotherapy and interval cytoreduction are non-inferior to primary cytoreduction and adjuvant chemotherapy with respect to overall and progression-free survival and are associated with less perioperative morbidity and mortality...
October 2016: Gynecologic Oncology
Denis Querleu, François Planchamp, Luis Chiva, Christina Fotopoulou, Desmond Barton, David Cibula, Giovanni Aletti, Silvestro Carinelli, Carien Creutzberg, Ben Davidson, Philip Harter, Lene Lundvall, Christian Marth, Philippe Morice, Arash Rafii, Isabelle Ray-Coquard, Andrea Rockall, Cristiana Sessa, Ate van der Zee, Ignace Vergote, Andreas du Bois
OBJECTIVES: The surgical management of advanced ovarian cancer involves complex surgery. Implementation of a quality management program has a major impact on survival. The goal of this work was to develop a list of quality indicators (QIs) for advanced ovarian cancer surgery that can be used to audit and improve the clinical practice. This task has been carried out under the auspices of the European Society of Gynaecologic Oncology (ESGO). METHODS: Quality indicators were based on scientific evidence and/or expert consensus...
September 2016: International Journal of Gynecological Cancer
Anselmo Papa, Davide Caruso, Martina Strudel, Silverio Tomao, Federica Tomao
BACKGROUND: Despite standard treatment for epithelial ovarian cancer (EOC), that involves cytoreductive surgery followed by platinum-based chemotherapy, and initial high response rates to these, up to 80 % of patients experience relapses with a median progression-free survival of 12-18 months. There remains an urgent need for novel targeted therapies to improve clinical outcomes in ovarian cancer. Of the many targeted therapies currently under evaluation, the most promising strategies developed thus far are antiangiogenic agents and Poly(ADP-ribose) polymerase (PARP) inhibitors...
2016: Journal of Translational Medicine
David Padilla-Valverde, Susana Sanchez-Garcia, Esther García-Santos, Carlos Marcote-Ibañez, Mercedes Molina-Robles, Jesús Martín-Fernández, Pedro Villarejo-Campos
PURPOSE: To determine the effectiveness of thermography to control the distribution of abdominal temperature in the development of a closed chemohyperthermia model Materials and Methods: For thermographic analysis, we divided the abdominopelvic cavity into nine regions according to a modification of carcinomatosis peritoneal index. A difference of 2.5º C between and within the quadrants, and thermographic colors, were used as asymmetric criteria. Preclinical study: Rats Model: Six athymic nude rats, male, rnu/rnu...
September 16, 2016: International Journal of Hyperthermia
Charles-André Philip, Aurélie Pelissier, Claire Bonneau, Delphine Hequet, Roman Rouzier, Nicolas Pouget
AIM: To assess the decrease in the number of bowel resections (BR) necessary to achieve complete cytoreduction (CC-0) in advanced epithelial ovarian cancer (EOC) permitted by neoadjuvant chemotherapy (NAC). PATIENTS AND METHODS: Patients were selected from a population of advanced EOC cases diagnosed between 2002 and 2009 at the Curie Institute: 97 patients with Federation International of Gynecology and Obstetrics IIIc and IV with unresectable disease treated with NAC followed by interval debulking surgery were included...
September 2016: Anticancer Research
Mustafa Zelal Muallem, Jumana Almuheimid, Rolf Richter, Elena Ioana Braicu, Suzan Osman, Jalid Sehouli
AIM: This study aimed to analyze diaphragmatic interventions and their complications in primary cytoreductive surgery (PCS) and to study their impact on attaining complete tumor resection (CTR) in advanced ovarian cancer (AOC), which is purportedly reflected in better disease-free and overall survival. PATIENTS AND METHODS: The study's collective consisted of 536 consecutive patients presenting a first diagnosis of AOC who underwent PCS between 2007 and 2013 at the Charité Medical University, Berlin...
September 2016: Anticancer Research
Kazuyoshi Kato, Hidetaka Nomura, Minoru Nagashima, Nobuhiro Takeshima
OBJECTIVE: We report the details of a cytoreduction technique for pelvic lymph node recurrence with involvement of the external iliac vein (EIV) requiring a partial resection and reconstruction of the EIV. METHODS: A 51-year-old woman presented with ovarian cancer and isolated nodal recurrence located on the right side of the pelvis. As the tumor had infiltrated the EIV wall, we performed the EIV excision and reconstruction using an autogenous graft. RESULTS: EIV reconstruction was achieved using a right ovarian vein patch...
September 11, 2016: Gynecologic Oncology
Alexander Melamed, Emily M Hinchcliff, Joel T Clemmer, Amy J Bregar, Shitanshu Uppal, Ian Bostock, John O Schorge, Marcela G Del Carmen, J Alejandro Rauh-Hain
OBJECTIVE: Neoadjuvant chemotherapy and interval debulking surgery for the treatment of advanced ovarian cancer has remained controversial, despite the publication of two randomized trials comparing this modality with primary cytoreductive surgery. This study describes temporal trends in the utilization of neoadjuvant chemotherapy and interval debulking surgery in clinical practice in the United States. METHODS: We completed a time trend analysis of the National Cancer Data Base...
September 6, 2016: Gynecologic Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"